Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study

Guselkumab selectively inhibits interleukin (IL)-23 and in psoriasis, produces high clinical responses including durable maintenance following treatment withdrawal in some patients. The relationships between IL-23 blockade, serum markers downstream of IL-23 signaling, and withdrawal were explored with guselkumab in VOYAGE 2.

Source: Journal of Investigative Dermatology - June 14, 2019 Category: Dermatology Authors: Kenneth B. Gordon, April W. Armstrong, Peter Foley, Michael Song, Yaung-Kaung Shen, Shu Li, Ernesto J. Mu ñoz-Elías, Patrick Branigan, Xuejun Liu, Kristian Reich Tags: Original Article Source Type: research